Cover Page

Universiteit Leiden

The handle http://hdl.handle.net/1887/25714 holds various files of this Leiden University dissertation.

Author: De Cock, Roosmarijn Frieda Wilfried
Title: Towards a system-based pharmacology approach to predict developmental changes in renal drug clearance in children
**Issue Date:** 2014-05-06

Chapter 2

The Role of Population PK-PD Modeling in Pediatric Clinical Research

Roosmarijn F. W. De Cock*, Chiara Piana*, Elke H.J. Krekels,
Meindert Danhof, Karel Allegaert, Catherijne A.J. Knibbe

*RDC and CP equally contributed to this paper

Abstract

Children differ from adults in their response to drugs. While this may be the result of changes in dose-exposure (pharmacokinetics (PK)) and/or exposure-response (pharmacodynamics (PD)) relationships, the magnitude of these changes may not be solely reflected by differences in bodyweight. As a consequence, dosing recommendations empirically derived from adults dosing regimens using linear extrapolations based on bodyweight, can result in therapeutic failure, occurrence of adverse effect or even fatalities. In order to define rational, patient tailored dosing schemes, population PK-PD studies in children are needed. For the analysis of the data, population modeling using non-linear mixed effect modeling is the preferred tool since this approach allows for the analysis of sparse and unbalanced datasets. Additionally it permits the exploration of the influence of different covariates such as bodyweight, age and other covariates, to explain the variability in drug response. Finally, using this approach, these PK-PD studies can be designed in the most efficient manner in order to obtain the maximum information on the PK-PD parameters with the highest precision. Once a population PK-PD model is developed, internal and external validations should be performed. If the model performs well in these validation procedures, model simulations can be used to define a dosing regimen which in turn needs to be tested and challenged in a prospective clinical trial. This methodology will improve the efficacy/safety balance of dosing guidelines which will be of benefit to the individual child.

2.1. Introduction

Children differ from adults in their response to drugs. These differences may be caused by changes in the pharmacokinetics (PK) and/or pharmacodynamics (PD) between children and adults and may also vary between children of different ages. The PK of a drug includes processes of absorption, distribution, metabolism and elimination of a drug whereas the PD comprises the physiological and biological response to the administered drug and therefore may represent both efficacy and safety measures. While a child grows, enzyme pathways (involved in the PK), function and expression of receptors and proteins (involved in the PD) mature, which can be referred to as 'developmental changes' in childhood. The maturation rates of these developmental changes vary however between the pathways and receptors and often do not correlate solely with the increase in bodyweight of the child. The question is

therefore how to obtain data in children that allow for the study of these developmental changes ultimately resulting in evidence based dosing regimens for drugs in children.

To date, only a small number of drugs used in children is licensed for use in this specific group. Up to 70% of the drugs in pediatric intensive care, and 90% of the drugs in neonatal intensive care, are prescribed in an off-label or unlicensed manner [1-4]. Pediatric dosing regimens are usually empirically derived from adult regimens using linear extrapolations based on bodyweight. Since these developmental changes are non-linear dynamic processes, this dosing paradigm may result in under or over-dosing particularly in specific age groups. This may cause therapeutic failure, occurrence of severe adverse effects or even fatalities such as fatalities occurring after long-term sedation with high doses of propofol [5, 6] and occurrence of the grey baby syndrome in neonates after treatment with chloramphenicol [7, 8]. As a result, dose adjustments in the younger age groups are often proposed. For vancomycin for example lower doses are administered in neonates younger than 1 week (20 mg/kg/day) compared to 1-4 week-old neonates (30 mg/kg/day) and children between 1 month and 18 years (40 mg/kg/day) [9].

Instead of the *a priori* use of bodyweight for dosing guidelines in children, detailed information on PK and potentially also the PD needs to be considered in order to define effective and safe dosing regimens throughout the pediatric age range. The lack of PK and PD information on drugs in children has lead to the European Regulation which entered into force in 2007. This law imposes pharmaceutical companies to perform research in the whole pediatric age-range for all drugs that are developed for the European market, by requiring the submission of a pediatric investigational plan (PIP) in the early stages of the development of a new drug. In this PIP, a full description has to be given of the studies and of drug formulation in the pediatric population. In case little information is available about efficacy and safety of a drug, studies in children are only performed after more information is obtained in the adult population to increase the safety of the pediatric study [10-12]. The main targets of introducing the Pediatric Regulation were to facilitate development and availability of medicines in children between 0 and 17 years, to improve the availability of information about medicines used in children, to ensure that the medicines are of high quality, can be administered in a safe and effective way and that pediatric studies are performed in an ethically correct way [10]. The reward for this effort is a six month supplementary production certificate for the pharmaceutical company.

Both for industry and for academic researchers, performing (PK-PD) studies in children in order to develop rational dosing schemes is very challenging because

of ethical and practical issues. Unlike studies in healthy adults, research in healthy children is considered to be unethical, so all pediatric studies are performed in the vulnerable group of children suffering from a disease. In all clinical trials, an informed consent has to be signed by the patient before he or she can be enrolled into a trial. In pediatric trials, this informed consent can not be obtained by the patient that participates in the trial, and is therefore replaced by the consent of the parents or guardians. In older age groups, in addition to this consent, an assent is used in which the aim of the study is explained in an age-appropriate language so that children can understand [1, 4, 13].

Apart from ethical issues, practical challenges also occur when performing studies in children. There are limitations to the number and volume of samples that can be obtained, resulting in infrequent sampling possibilities and the need for advanced drug assay techniques with improved sensitivity. Another complicating factor is the limited available number of subjects that suffers from the same disease. Finally, pharmaco-dynamic endpoints that measure the efficacy of the drug, and which are validated for children may be lacking. All these factors call for highly advanced study designs and analysis techniques so that the burden for each child can be kept to a minimum while still addressing all the study objectives.

This paper aims to inform clinical pharmacologists, pediatricians and pharmacists about population PK-PD modeling in pediatric drug research. Advanced statistical tools are discussed that can be used to develop rational dosing schemes based on the PK and PD of a drug in children, despite practical and ethical restrictions. Using these tools, covariates can be identified in order to define appropriate doses and dosing intervals based on individual characteristics of each child with minimal burden to each patient. The paper also describes how to evaluate the predictive performance of the models by different validation methods including a prospective clinical trial. Ultimately, the efforts result in an individualized dosing regimen based on the PK-PD relation through the pediatric age-range.

2.2. PK-PD in children

Developmental changes in childhood can affect all PK processes from absorption until elimination as well as the pharmacodynamic effects. For example, in neonates intra-gastric pH is elevated (>4) which may increase the bioavailability of acid-labile compounds (penicillin G) and decrease the bioavailability of weak acids (phenobarbi-tal) when given orally [14]. Additionally, gastric emptying in neonates is delayed, which

means that also the absorption of drugs e.g. paracetamol is slower in neonates [15, 16]. Other examples are changes in metabolizing enzyme capacity in children. Although most uridine 5'-diphosphate (UDP)-glucuronosyltransferases (UGTs) and P-450 cytochromes (CYPs) are expressed during the first week of life, the activity at birth in comparison with adults is often low, e.g. UGT2B7 activity at birth is around 10% of the adult level and maturation rates of different enzyme systems are known to mature at different rates [14, 17-20].

In addition, renal function and liver flow are influenced by physiological changes depending on age, e.g. the glomerular filtration rate in mL/min/70kg in full term neonates is 35% of the adult value, while mL/min/70kg adult values are reached at approximately 1 year old [21]. When using units of mL/min/70kg however, it should be realized that actual values of GFR in children are still very low compared to adult values because of correction for differences in total body weight between adults and infants.

Furthermore the body composition of children changes continuously resulting in an age-dependent proportion of body water and fat, which influences the distribution of drugs. For example, the total amount of body water (80-90 % of the bodyweight) is higher in neonates compared to adults (55-60%). Hydrophilic drugs like aminoglycosides have a larger volume of distribution in neonates which can be explained by larger extra-cellular fluid (45% of the bodyweight) compared to adults (20%) [14, 22].

In order to characterize the specific influence of developmental changes in childhood on the PK of a drug, concentration-time profiles are necessary, which require measurements of drug concentrations. For ethical reasons, in pediatric studies, discomfort, like pain and anxiety associated with venipuncture, must be restricted and practical issues limit the volume and amount of blood samples that can be obtained. Therefore, sensitive analysis techniques requiring only small blood samples should be used. While HPLC methods have reported to require only 50 µL of blood [23], more recently LC-MS methods can measure up to ten different drugs in volumes as low as 50-100 µL [24]. Additionally, also alternative matrices such as saliva should be explored as a non-invasive, more child-friendly alternative to measure a drug concentration. An example in this respect is a LC-MS/MS method which was developed and validated for the measurement of busulphan in saliva [24]. Also the use of a dried blood spot method e.g. for tacrolimus can facilitate the measurement of drugs in children [25]. Another method is capillary electrophoresis which requires only a low sample volume for the quantification of drugs in biological fluids [26].

Changes between children and adults may also result from differences in the

pharmacodynamics of a drug in children, e.g. by changes in the relative number and function of receptors. These age-related PD differences are until present rarely reported in literature, but one of the few examples is the increased sensitivity to d-tubocurarine, an antagonist of nicotinic neuromuscular acetylcholine receptors, in neonates and infants compared to children and adults [27]. Other examples are the observed lower minimum alveolar concentration (MAC) of isoflurane in preterm neonates compared to full-term neonates and older children [28, 29] and the different sensitivity to bronchodilators because of the lack of smooth muscles in the airways in neonates [30].

To study the PD of a drug in children, the use of a PD endpoint which is validated for use in children is a prerequisite. An illustrative example is the measurement of pain in young children. Since they are not able to report their pain using a visual analogue scale, an observational scale has been developed. This comfort behavioral (COMFORT-B) scale was developed and validated for use in children under the age of three years [31]. The scale assesses six behavioral items: alertness, calmness, muscle tone, body movement, facial tension, and crying (non-ventilated children) or respiratory response (ventilated children). All items range from 1 (no distress) to 5 (severe distress), resulting in a total score of varying from 6 to 30. This validated scale can then be used as a PD endpoint for the development of PD models for pain and/or sedation in children of different ages [32-34].

The influence of covariates such as the developmental changes, disease status and genetics on the PK and PD of drugs in children is depicted in Figure 1.


Figure 1: Schematic representation of the relationship between dose and concentration (pharmacokinetics, PK) and between concentration and a pharmacological (side) effect (pharmacodynamics, PD). Important covariates which may affect both the PK and/or PD are bodyweight, age, disease status (e.g. critically ill *versus* healthy children) and genetics.

When both the PK and PD of a drug in children are characterized, the developed models can be used to derive rational dosing regimens with predictable efficacy and concentration profiles. An example of such a PK-PD model with a derived dosing regimen is an article published by Peeters *et al.* In this paper both the PK and the PD were characterized in children, the latter with the use of the COMFORT-B scale as pharmacodynamic endpoint [33]. Based on the model it was found that propofol clearance is two times higher in non-ventilated children compared to ventilated children and adults. For the PD, a model was derived in which an effect of propofol was characterized within a naturally occurring sleep pattern of children in the ICU. Both models (PK as well as PD) were used to simulate concentrations as well as the effects that could be expected using different dosing schemes (Figure 2). As a result, based on this PK-PD model, a propofol dose of 30mg/h was recommended for a child of 10 kg which will result in adequate COMFORT-B scales in the night following craniofacial surgery.


Figure 2: Simulation of propofol concentrations and response using COMFORT-B score *versus* time based on developed PK and PD models, after administration of different doses of propofol (0, 18, 30, and 36 mg/h) for a 10 kg and a 5 kg non-ventilated infant in the first night at the Intensive Care following craniofacial surgery. Target COMFORT-B scores are between 12 and 14 preferably. Reproduced from [Peeters MY, Prins SA, Knibbe CA, DeJongh J, van Schaik RH, van Dijk M, *et al.* Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology 2006 Mar;104(3):466-74.]

2.3. Methods to analyse data: standard two-stage or population approach

When concentration-time and concentration-effect datasets obtained in children are considered for analysis, two different methods can be applied: the standard two-stage approach and the population approach using non-linear mixed effect models [35-38]. When using the standard two-stage approach or classical approach, in a first step parameters are estimated in each individual based on individual concentration-time profiles (figure 3A). In a second step, these parameters are summarized by calculating the mean or median of the parameters and the variability between subjects (SE or IQR). A major drawback of this methodology is that this approach requires a relatively high number of samples in each individual patient (Figure 3A) while each patient has to contribute roughly the same number of samples. Moreover it is very difficult to distinguish between inter-individual (variability between subjects), intra-individual and residual variability (variability within one subject, measurement error, and model misspecification) and as a result inter-individual variability is often overestimated [39].

Since usually only a limited number of observations can be obtained in pediatric subjects, the population approach using non-linear mixed effect modeling to obtain PK and PD parameters, is the preferred approach [37]. The population approach differs from the standard two stage-approach in the fact that the analysis is based on simultaneous analysis of all data of the entire population while still taking into account that different observations come from different patients (Figure 3B). Additionally the population approach allows not only for the analysis of dense data but also for sparse (limited number of observations per individual) and unbalanced data (unequal distribution of observations in various parts of the concentration-time profile in the individuals) or a combination of both. Finally both the interindividual and intra-individual variability are separately estimated in the dataset using this approach.

As a result of this methodology, when designing a pediatric study of which the data will be analyzed using the population approach, it is advisable to collect samples at different times (or time-windows) or to s*et al*ternating sampling schemes in subgroups of patients. This also means that (part of the) samples can be collected during routine clinical sampling. Consequently, the burden for the child that participates in the trial is reduced and the statistical power to develop a model describing the concentration-time or concentration-effect profile is not affected or improved.

Figure 3: Concentration-time profiles of the same study using two different approaches. In figure 3A the standard two-stage approach is applied to a rich dataset. 3B shows the population approach with mixed effect modeling applied to the same dataset using only two datapoints for each individual so a sparse dataset is created. In 3A, in each of the six individuals 10 samples are available. The different symbols correspond to different individuals. Each black line corresponds to a separate fit to the 10 data points of each individual.

In 3B, which uses the mixed effect modeling approach, two samples of the 10 per subject in 2A are used. The different symbols correspond to the six different individuals. The black line illustrates the concentration time plot based on the population mean values of the PK parameters (PRED). The grey lines show the plots of the individual patients, which are based on the population mean values together with the measured concentrations of the specific individual (IPRED).

The term 'mixed' in non-linear mixed effects modeling stands for a mixture of fixed and random effects. For the fixed effects, a structural model describing the PK or PD is chosen (e.g. a two-compartment model for PK or an E_{max} model for PD). The random effects quantify the variability that is not explained by the fixed effects. These random effects include inter-subject and intra-subject and random variability (Figure 4), which are both simultaneously and separately estimated. It is often assumed that the variability between subjects follows a normal distribution with a mean of zero and variance ω^2. Equation 1 is used to describe the relationship between individual and population parameter estimates.

$$\theta_i = \theta_{mean} \bullet e^{\eta i}$$

(Equation 1)

where θ_i represents the parameter of the ith subject, θ_{mean} the population mean, and ηi the variability between subjects. The residual error is in generally described

using a proportional error (error is dependent on the concentration, which means a higher absolute error at higher concentrations (equation 2)) or additive error (constant for all observations (equation 3)) or a combination of both. This means for the jth observed concentration of the ith individual the relation (Y_{ij}):

$$Y_{ij} = C_{pred,ij} \bullet (1 + \varepsilon_{ij})$$

(Equation 2)

$$Y_{ij} = C_{pred,ij} + \varepsilon_{ij}$$

(Equation 3)

where c_{pred} is predicted concentration and ε_{ij} is a random variable with mean zero and variance σ^2.

In general, model building requires three different steps. First a structural model (fixed effects) has to be designed, then a statistical sub-model (random effects) has to be developed and in the final step a covariate sub-model is identified.

The structural model describes the overall trend in the data. The choice of structural model (e.g. one, two or three-compartment model for PK and an Emax model for PD) is to be based upon the best *a priori* information about the drug to be studied [40]. The structural model uses fixed effects parameters such as clearance and volume of distribution for PK or E_{max} and EC_{50} for PD. The population values for these parameters are called typical values (TV).

After selecting the structural model, the statistical sub-model which accounts for the inter-individual as well as the residual variability is chosen and tested. Information on both inter- and intra- and residual variability is of clinical value, because it describes differences in clinical response between and within patients and may therefore provide guidance to rational dose adjustments. With the population approach, both these random effects are obtained, apart from estimates of both the population values (TV) and the individual values of PK and PD parameters (so called *post hoc* parameter estimates).

In the final step the covariate sub-model is determined which expresses relationships between covariates and parameters of the structural model (e.g. influence of bodyweight on volume of distribution or clearance). Covariates can be individual-specific (age, bodyweight, genetic profile, etc) or time-varying (renal

function, hemodynamic parameters, body temperature etc). The covariate analysis will be explained more in details in the following section.

As these three models are interrelated, the choice of the structural (and statistical) model may affect the choice of the covariate model and vice versa. The process of finding a model that adequately describes the data is thus an elaborate task, where model checking/refining is performed in several steps. To assess model fit in relation to the observed concentrations or effect measures, scatter plots or the so called goodness-of-fit plots are created (see Validation of the PK-PD models). Free software packages (Xpose, PSN etc.) are available to generate these plots.

The most commonly used software package for model building, which is also supported by the European Medicines Agency (EMEA) is the nonlinear mixed-effect modeling program NONMEM (GloboMax/ ICON, Ellicott City, MD) [4, 41-43]. NONMEM estimates parameters (e.g. clearance, volume of distribution or EC_{50}) via a maximum likelihood approach. This means that with the given data, the estimations of the parameters are the estimations which occur with the highest probability. Alternative software packages that can be used are for example Monolix, WinNonMix, USC*PAC which uses nonparametric maximum likelihood methods [44] or ADAPT using maximum *a posteriori* (MAP) methods [45].


Figure 4: In 4A, the inter-individual variability is shown between three individuals who received the same dose. 4B presents the intra- or residual variability by showing the concentration-time profile after repeated administration. Both these random variables are assumed to be normally distributed with a mean of zero and a variance of ω^2 or σ^2 respectively.

2.4. Covariate analysis

To determine the optimal dose based on the individual characteristics of a patient, a covariate analysis has to be performed [40, 46, 47]. The aim of the covariate analysis is to identify specific predictors (covariates) of PK and PD variability and can typically be studied in population models. Covariate analysis involves the modeling of the distribution of the individual parameter estimates as a function of covariates which can be of demographic (e.g. age, bodyweight, gender), patho-physiological (e.g. renal or hepatic function), and genetic/environmental origin and/or be the result of the concomitant use of other drugs, which may influence the PK and/or PD. The identification of predictive covariates for variability provides the scientific basis for rational and individualized, patient tailored dosing schemes.

The influence of developmental changes in childhood can be explored primarily by using size and/or age as covariates. Size (bodyweight) can be incorporated into the model using two different approaches. The first approach or 'allometric size approach' includes size *a priori* by using a bodyweight based exponential equation with a fixed exponent of 0.75 for clearance and 1 for volume of distribution [48-52]. Once size is incorporated in the model using this fixed manner, the influence of age is investigated, being the difference between actual value of the PK parameter and the 0.75 allometric equation. When incorporating age as a covariate, different age descriptors may be used like postmenstrual age (PMA), gestational age (GA) or postnatal age (PNA) [53]. The choice for any of these age descriptors is based on the results of the systematic covariate analysis as described below [50, 54]. In the second approach or 'systematic covariate analysis', bodyweight is regarded as a covariate as any other which means that the descriptive properties on the PK parameters are evaluated in a systematic covariate analysis as described below [55-57].

In a systematic analysis, when studying the influence of covariates, scatter plots and summary plots of individual parameter estimates and/or weighted residuals *versus* covariates are used to screen for appropriate covariates to include in the covariate sub-model. Additionally these plots are used to explore the nature of the influence of the covariate (linear, exponential, allometric, subpopulations etc). Likely candidate covariates are then added to the model (forward inclusion). The influence of each covariate on the parameters is examined separately and compared to the simple model (no covariates). To assess whether the model with covariate statistically improved the fit to the data, the difference between their objective function value, referred to as log-likelihood ratio, is calculated. This ratio is assumed to be Chi-

square distributed, which means that a reduction in objective function of 3.84 is considered to be significant (P<0.05) [43, 58]. Beside the reduction in objective function, goodness-of-fit plots of the simple model and covariate model are explored for diagnostic purposes. Furthermore, the confidence interval of the parameter estimates, the correlation matrix (indicates the relationship between two structural parameters) and visual improvement of the individual plots are used to evaluate the model. Finally, a superior model is expected to reduce the inter-subject variance and/or the residual error terms. This procedure of covariate modeling implies that each covariate is only implemented if this can be fully justified by the data and the results of the statistic evaluations.

When two or more covariates are found to significantly improve the model the covariate that reduced the objective function most is included in the model after which the other covariates are tested again for their significance. After all covariates that significantly improved the objective function are added to the simple model, a backward deletion is performed, which means that each covariate is removed from the full model, one at a time (the one which causes the smallest increase in objective function first). Retaining or removing the covariate is statistically tested by the use of the objective function (Chi-square test) until each covariate has been tested.

In datasets containing sparse data, there may not be enough information to accurately estimate inter- and intra-individual variability. This causes the values of these parameters to shrink to 0, resulting in individual parameter estimates that are closer to the population parameter estimates than they really are. This phenomenon is called shrinkage [59]. Shrinkage may cause individual predictions, individual parameter estimates and diagnostics based on them to be less reliable. It can also hide, falsely introduce or distort the shape of covariate relationships.

Shrinkage is the result of properties of the data and is therefore difficult to avoid. One can only be aware of the presence of shrinkage, realize the influence it may have on the covariate analysis and use diagnostics other than those based on individual predictions or individual weighted residuals in the model building and model evaluation procedures.

2.5. Validation of PK-PD models

The objective of a PK or PK-PD modeling exercise is usually not just to describe the dataset of the sample of individuals that were studied. Generally, models are used

to simulate which concentrations and/or effects and their variability can be expected when different doses are given to future patients. These simulations may therefore lead to optimized dosing recommendations or to optimization of new studies for the entire population where the sample of individuals belongs to. It is often said that 'all models are wrong, but some are useful' [60]. In order to define whether a model is useful and valid for clinical and trial simulations, thorough evaluation and validation of the model is necessary. Although validations of PK models are only performed in 17% of the published pediatric studies [4] and in 28% of the adults studies [61], proper model validations are an essential step in model building. For this purpose, different evaluation and validation methods are available. As described before [62], a proper validation and evaluation procedure includes an internal model evaluation followed by an external evaluation and a prospective clinical study.

The first evaluation method is the basic internal model validation used to assess whether the model is able to describe the learning dataset (dataset used to develop the model) accurately and without bias. This evaluation should actually be considered the final stage of the model building procedure. Subsequently, in the external evaluation it is assessed whether the model is able to describe one or more external datasets (datasets other than the one used to develop the model) adequately. Alternatively if a dataset is sufficiently large the original dataset may be split in two so that the model is developed using one part (about two thirds) of the dataset and evaluated externally using the other part (one third) of the dataset. In pediatric studies, it is then especially important to stratify the data correctly and ascertain that all age groups are represented in equal proportions in both datasets.

Various techniques are available for the validation and evaluation of population PK and PK-PD models (both for internal and external validation procedures).

- Basic goodness-of-fit plots ((1) individual predicted *versus* observed concentrations, 2) population predicted *versus* observed, 3) (conditional) weighted residuals *versus* time and 4) (conditional) weighted residuals *versus* dependent variable plots). *WRES* and *CWRES* are calculated as the following:

$$WRES = \frac{y_i - E_{FO}(y_i)}{\sqrt{Cov_{FO}(y_i)}}$$

(Equation 4)

$$CWRES = \frac{y_i - E_{FOCE}(y_i)}{\sqrt{Cov_{FOCE}(y_i)}}$$

(Equation 5)

- Where y_i is the vector of measurements, $E(y_i)$ is the expectation of the data and $Cov(y_i)$ is the covariance matrix of the data [63].

- These plots are used in model building, but can also be used to ascertain that there is no trend or bias in the model predictions of the final model. Furthermore, these plots can also be used for both the internal and external evaluation of the model.

- In a bootstrap analysis new datasets are generated by resampling from the original dataset and is therefore an internal validation of the model. The new datasets are subsequently refitted to the original model, yielding mean values and standard errors for every model parameter.

- A bootstrap analysis provides information on the stability of the model and its dependence on specific individuals in the learning dataset. With the freely available PSN or Wings for NONMEM software packages an automated bootstrap analysis can be performed.

- In a visual predictive check (VPC) [64] a PK or PD profile is simulated a 100 to 1000 times and lines for the median values and their 90% prediction interval are plotted in a graph. The observed values in the internal or external dataset are subsequently plotted on top of this. It can then be visually checked whether 90% of the observations are within the indicated prediction interval and whether there is no bias in the observations compared to prediction interval. In figure 5, two examples of a VPC are given, showing when a model does not work and when a model does work on the same data.

- The VPC is a simulation-based diagnostic that can be used when the PK or PD profiles for all individuals in the dataset are similar and it allows for easy interpretation of the result. For this diagnostic tool, there are not statistical tests and all evaluations are based on visual evaluations. When the individual profiles are expected to deviate largely from one another because there is for instance a large variability in the time and amount of dose administrated, or when there are many covariates, the use of this diagnostic becomes more difficult.

- Another simulation-based diagnostic which can be used for both internal and external validations is the normalized prediction distribution error (NPDE) [65]. An example of an NPDE published before is shown in figure 6 [55]. This method yields information on how accurate the model predicts the median

value of the observations and the variability within them. The interpretation of this diagnostic is less straightforward than for the VPC, but the advantage of this method is that it can be used when the variability in dosing regimen (both in time, amounts and rates) is high or when there is a large number of covariates in the model. This can for instance be the case for data obtained during routine pediatric clinical practice. Software (e.g. NPDE add-on package for R) [66] to perform this analysis is freely available. For the NPDE, beside visual evaluation of the plots, statistical tests are available. These statistical tests are however reported to be highly sensitive and powerful, so that decisions for the model should primarily be based on visual assessments. An example is the statistically significant deviation of zero of the mean value because of the large number of data, while the actual deviation is small (e.g. 0.074) and not of clinical relevance.

If the model performed well in both the evaluation procedures, the dosing algorithm that results from the PK-PD model needs to be tested and challenged in a prospective (clinical) trial. If the predictive performance of the model is corroborated by the trial it can be used with confidence in clinical practice.


Figure 5: Two examples of a visual predictive check (VPC) are illustrated based on the same dataset (warfarin concentrations and prothrombin complex activity (PCA)) using two different models. In 5A the VPC of the effect compartment model is shown, while in 5B the VPC of the turnover model is demonstrated. The median (black thick line) and the 90% intervals (black thin lines) together with the observed data (PCA) (dots) are shown. Based on both graphics, the turn over model is the most appropriate model since 90% of the observations are lying within the prediction interval. Furthermore, unlike the effect compartment model, no bias is seen in the observations. Reproduced from [Holford N, 2005. The visual predictive check - Superiority to Standard Diagnostic (Rorschach) Plots. PAGE 14, Abstr 738. (http://www.page-meeting.org/?abstract=738)].

Figure 6: Example of a normalized prediction distribution error (NPDE) analysis, which show the NPDE distributions for morphine. The normal distribution is presented by the solid line. The values for the mean and standard deviation of the observed NPDE distribution are given below the histogram, with * indicating a significant difference of a mean of 0 and a variance of 1 at the p<0.05 level, as determined by the Wilcoxon signed rank test and Fisher test for variance. Additionally the distribution of NPDE vs time after the first dose and NPDE vs the log of the concentrations are also shown. The dotted lines represent the 90% distribution of the NPDE. Reproduced from [Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van Dijk M, *et al*. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet2009;48(6):371-85] with permission from Wolters Kluwer Health | Adis (© Adis Data Information BV [2006]. All rights reserved.)

2.6. Optimal design of pediatric studies

When new population PK-PD studies are performed, it is important to design these studies in the most efficient manner possible to obtain maximum information about the PK and PD parameters so that they can be determined with the highest precision [51, 67]. When designing PK-PD studies in pediatrics certain factors need to be taken into account e.g. age-range of the pediatric group, therapeutic index, possibility to collect blood samples, availability of validated PD endpoints for children, and the availability of sensitive analytical methods.

When optimizing a PK or PK-PD study design, using literature data from adults or children of different age-ranges or possible *in vitro* or pre-clinical data, a concentration-time or effect-time profile for a study can be simulated. This can help to identify possible shortcomings in the design or to perform a power-analysis. Alternatively software packages are available (WINPOPT [68], PopED [67] and PFIM [69]) that can help to identify the optimal number and time points of observations in a study based on the prior information on a drug [70]. To determine the appropriate sample size certain

factors, which are summarized in Table 1, need to taken into account. Each of these factors can influence the required number of patients and/or samples in a positive or negative way. In a study of Peeters *et al.* [32] only 24 patients (aged between 3 and 24 months) were required to determine both the PK and PD since rich sampling was performed (median of 11 samples per child) and no covariates were found in the relatively homogenous population. This in contrast to a study performed by Knibbe e*t al.* [55] in which 250 children were included. This higher number was required because in addition to the large dispersion in age from (preterm) neonates up to toddlers of 3 years of age, only 1 to 4 samples were available for each subject. Moreover infusion rates and additional bolus doses varied for each child during the study to obtain the desired analgesic effect. In another example [71], only 6 patients (aged between 1 and 5 years) were required in which 7 samples per patient were collected. This lower number of patients (N=6) compared to the study of Peeters *et al.* (n=24) can be explained because there often exist a lower variability in PK than in PD which results in a lower required number of patients (Table 1).

Table 1: Factors influencing the required number of patients and/or samples per patient.

Factor	Number of patients/samples
Study of PK only	relatively small number of patients/samples
Study of PK-PD relationship	relatively high number of patients/samples
Even distribution of covariates (age, bodyweight)	↓ number of patients/samples
↑ Number of changes in dose	↑/- number of patients/samples (depending on other aspects of the study design)
↑ Number of samples/child	↓ number of patients
Use of optimal sampling strategies	↓ number of patients/samples
Different sampling windows(e.g. two or three sampling schemes)	↓ number of patients/sample

2.7. Conclusions and perspectives

In view of the European Regulation which came into force in 2007, it seems now time to use the progress that has been made in the field of integrated PK-PD modeling [72] to develop rational and individualized dosing schemes for children. Because of the possibility to analyse sparse and unbalanced datasets thereby minimizing the burden for each child, population PK-PD modeling and simulation using non-linear mixed effect modeling has become the preferred tool to develop effective and safe dosing regimens for children. Specifically in pediatrics where the developmental changes have to be taken into account, which may influence the PK and/or the PD of the drugs, this advanced statistical tool is of critical value.

Before dosing regimens can be tested in clinical practice, proper validations of the models should be performed, for which recently adequate tools have been developed. Beside internal and external validations, prospective clinical trials, which allow for the evaluation of the model based dosing regimens, are needed, not only to adjust the proposed dosing regimen but also to convince pediatricians to use the information that has been generated using these modeling exercises.

Furthermore, one of the future goals may be to explore possibilities for cross-validation of the models, in which the reported influences of developmental changes on a certain PK or PD parameter of one drug are evaluated for use in another drug that go through the same metabolic route or share the same mechanism of action. In this respect, physiologically-based pharmacokinetic (PBPK) models are needed. PBPK models consider the physiological and biochemical processes by using *in vitro* data to describe the PK of drugs [73, 74]. The combination of these two approaches may use the information that is already available in a more optimal way in defining effective and safe dosing regimens for every individual patient.

In conclusion, analyses of pediatric data using population PK-PD modeling and covariate analysis will result in individualized dosing regimens for children of different age, bodyweight and genetic background. Thus population PK-PD modeling constitutes an innovative approach to the study of drug effects in this very special patient population, which is otherwise difficult to study.

Acknowledgements

References

1. Ernest TB, Elder DP, Martini LG, *et al* (2007) Developing pediatric medicines: identifying the needs and recognizing the challenges. J Pharm Pharmacol 59 (8): 1043-1055

2. t Jong GW, Vulto AG, de Hoog M, *et al* (2001) A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics 108 (5): 1089-1093

3. Conroy S, Choonara I, Impicciatore P, *et al* (2000) Survey of unlicensed and off label drug use in pediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 320 (7227): 79-82

4. Tod M, Jullien V, Pons G (2008) Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 47 (4): 231-243

5. Bray RJ (1998) Propofol infusion syndrome in children. Paediatr Anaesth 8 (6): 491-499

6. Parke TJ, Stevens JE, Rice AS, *et al* (1992) Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 305 (6854): 613-616

7. Sutherland JM (1959) Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. AMA J Dis Child 97 (6): 761-767

8. McIntyre J, Choonara I (2004) Drug toxicity in the neonate. Biol Neonate 86 (4): 218-221

9. Nederland Kenniscentrum Farmacotherapie bij Kinderen. (http://www.kinderformularium.nl) Accessed on 29 June 2009.

10. European Medicines Agency (EMEA): Medicines for children. (http://www.emea.europa.eu/htms/human/pediatrics/introduction.htm) Accessed on Accessed 17 June 2009.

11. Dunne J (2007) The European Regulation on medicines for pediatric use. Paediatr Respir Rev 8 (2): 177-183

12. Consultant PR (2006) EU pediatric regulation for testing medicines in children.(http://www.child-medicines-research-info.com/pediatric-research-consultancy/eu-pediatric-regulation.asp) Accessed on 23 June 2009.

13. Saint Raymond A, Brasseur D (2005) Development of medicines for children in Europe: ethical implications. Paediatr Respir Rev 6 (1): 45-51

14. Kearns GL, Abdel-Rahman SM, Alander SW, *et al* (2003) Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med 349 (12): 1157-1167

15. Grand RJ, Watkins JB, Torti FM (1976) Development of the human gastrointestinal tract. A review. Gastroenterology 70 (5 PT.1): 790-810

16. Anderson BJ, van Lingen RA, Hansen TG, *et al* (2002) Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology 96 (6): 1336-1345

17. Hines RN, McCarver DG (2002) The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 300 (2): 355-360

18. de Wildt SN, Kearns GL, Leeder JS, *et al* (1999) Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 36 (6): 439-452

19. Leeder JS (2004) Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discov Today 9 (13): 567-573

20. Krekels EH, van den Anker JN, Baiardi P, *et al* (2007) Pharmacogenetics and pediatric drug development: issues and consequences to labelling and dosing recommendations. Expert Opin Pharmacother 8 (12): 1787-1799

21. Rhodin MM, Anderson BJ, Peters AM, *et al* (2009) Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 24 (1): 67-76

22. Bartelink IH, Rademaker CM, Schobben AF, *et al* (2006) Guidelines on pediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 45 (11): 1077-1097

23. Knibbe CA, Koster VS, Deneer VH, *et al* (1998) Determination of propofol in low-volume samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 706 (2): 305-310

24. Rauh M, Stachel D, Kuhlen M, *et al* (2006) Quantification of busulfan in saliva and plasma in haematopoietic stem cell transplantation in children : validation of liquid chromatography tandem mass spectrometry method. Clin Pharmacokinet 45 (3): 305-316

25. Edelbroek PM, van der Heijden J, Stolk LM (2009) Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 31 (3): 327-336

26. Jabeen R, Payne D, Wiktorowicz J, *et al* (2006) Capillary electrophoresis and the clinical laboratory. Electrophoresis 27 (12): 2413-2438

27. Fisher DM, O'Keeffe C, Stanski DR, *et al* (1982) Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. Anesthesiology 57 (3): 203-208

28. LeDez KM, Lerman J (1987) The minimum alveolar concentration (MAC) of isoflurane in preterm neonates. Anesthesiology 67 (3): 301-307

29. Blusse van Oud-Alblas HJ PM, Brill MJE, Knibbe CAJ, Klein J, Tibboel D, Weber F (2009)

The pharmacodynamics of isoflurane in children using Bispectral index and composite auditory evoked potentials. .(www.page-meeting.org/?abstract=1576 Accessed on

30. Stephenson T (2005) How children's responses to drugs differ from adults. Br J Clin Pharmacol 59 (6): 670-673

31. van Dijk M, de Boer JB, Koot HM, *et al* (2000) The reliability and validity of the COMFORT scale as a postoperative pain instrument in 0 to 3-year-old infants. Pain 84 (2-3): 367-377

32. Peeters MY, Prins SA, Knibbe CA, *et al* (2006) Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology 105 (6): 1135-1146

33. Peeters MY, Prins SA, Knibbe CA, *et al* (2006) Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology 104 (3): 466-474

34. van Dijk M, Peters JW, van Deventer P, *et al* (2005) The COMFORT Behavior Scale: a tool for assessing pain and sedation in infants. Am J Nurs 105 (1): 33-36

35. Jonsson EN, Karlsson MO (1999) Xpose--an S-PLUS based population pharmacokinetic/ pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58 (1): 51-64

36. FDA C (1999) Guidance for industry. Population pharmacokinetics. (http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072137.pdf

37. FDA C (1998) Guidance for industry. General considerations for pediatric pharmacokinetic studies for drugs and biological products (Draft Guidance).(http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072114. pdf) Accessed on 22 June 2009.

38. Beal SL, Sheiner LB (1982) Estimating population kinetics. Crit Rev Biomed Eng 8 (3): 195-222

39. Ette EI, Williams PJ, Lane JR (2004) Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies. Ann Pharmacother 38 (12): 2136-2144

40. Wade JR, Beal SL, Sambol NC (1994) Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. J Pharmacokinet Biopharm 22 (2): 165-177

41. Aarons L (1999) Software for population pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 36 (4): 255-264

42. Beal SL SL, Broeckman AJ (2006) NONMEM Users Guides. Icon Development Solutions, Ellicott City, Maryland, USA.

43. Broeckman AJ SL, Beal SL (1994) NONMEM Users Guide - Part V. University of California at San Francisco, San Francisco.

44. Jelliffe R SA, Van Guilder M, *et al.* (1995) User manual for version 10.7 of the USC*PAC Collection of PC Programs, USC Laboratory of Applied Pharmacokinetics. USC School of Medicine, Los Angeles.

45. Bustad A, Terziivanov D, Leary R, *et al* (2006) Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 45 (4): 365-383

46. Mentre F, Mallet A (1994) Handling covariates in population pharmacokinetics. Int J Biomed Comput 36 (1-2): 25-33

47. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20 (5): 511-528

48. Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48: 303-332

49. Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: general principles. Eur J Pediatr 165 (11): 741-746

50. Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 165 (12): 819-829

51. Meibohm B, Laer S, Panetta JC, *et al* (2005) Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 7 (2): E475-487

52. Anderson BJ, Holford NH (2009) Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24 (1): 25-36

53. Engle WA (2004) Age terminology during the perinatal period. Pediatrics 114 (5): 1362-1364

54. Allegaert K, Anderson BJ, Cossey V, *et al* (2006) Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol 61 (1): 39-48

55. Knibbe CA, Krekels EH, van den Anker JN, *et al* (2009) Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 48 (6): 371-385

56. Mahmood I (2007) Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther Drug Monit 29 (3): 271-278

57. Mahmood I (2009) Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metabol Drug Interact 24 (1): 57-81

58. Sheiner LB, Ludden TM (1992) Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 32: 185-209

59. Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82 (1): 17-20

60. Box G (1979) Robustness in the strategy of scientific model building. In: Launer RL Wilkinson GN,editors. Robustness in Statistics. New York: Academic Press, pp202.

61. Brendel K, Dartois C, Comets E, *et al* (2007) Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 46 (3): 221-234

62. Ince I, de Wildt SN, Tibboel D, *et al* (2009) Tailor-made drug treatment for children: cre-

ation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today 14 (5-6): 316-320

63. Hooker AC, Staatz CE, Karlsson MO (2007) Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 24 (12): 2187-2197

64. Fang L, Holford NH, Hinkle G, *et al* (2007) Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol 47 (2): 227-237

65. Brendel K, Comets E, Laffont C, *et al* (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23 (9): 2036-2049

66. Comets E, Brendel K, Mentre F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90 (2): 154-166

67. Foracchia M, Hooker A, Vicini P, *et al* (2004) POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed 74 (1): 29-46

68. Duffull SB DN, Eccleston, J, Kimko, H (2008) WinPOPT User Guide Version 1.2. School of Pharmacy, University of Otago, New Zealand.

69. Retout S, Mentre F (2003) Optimization of individual and population designs using Splus. J Pharmacokinet Pharmacodyn 30 (6): 417-443

70. Duffull SB (2001) Design of clinical pharmacology trials. Clin Exp Pharmacol Physiol 28 (11): 905-912

71. Knibbe CA, Melenhorst-de Jong G, Mestrom M, *et al* (2002) Pharmacokinetics and effects of propofol 6% for short-term sedation in pediatric patients following cardiac surgery. Br J Clin Pharmacol 54 (4): 415-422

72. Breimer DD (2008) PK/PD modelling and beyond: impact on drug development. Pharm Res 25 (12): 2720-2722

73. Alcorn J, McNamara PJ (2008) Using ontogeny information to build predictive models for drug elimination. Drug Discov Today 13 (11-12): 507-512

74. Johnson TN (2005) Modelling approaches to dose estimation in children. Br J Clin Pharmacol 59 (6): 663-669